All In Biotech

Drug Trial Radar · NCT05299658

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 13, 2021

Primary completion

Jun 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Clene NanomedicineIndustry
Sponsor type
Industry
First posted
Mar 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • CNMAu8Drug

    CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety measuresTime frame: Up to an estimated 96 weeks.
  2. Electromyography measuresTime frame: Up to an estimated 96 weeks.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Concord Hospital

    Concord, New South Wales, Australia

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.